Introduction {#ejhf1452-sec-0004}
============

Heart failure (HF) remains a major cause of mortality and morbidity in industrial countries representing the most frequent reason for hospitalization.[1](#ejhf1452-bib-0001){ref-type="ref"}, [2](#ejhf1452-bib-0002){ref-type="ref"} Due to demographical changes and promoted by current medical progress -- i.e. lower mortality rates from ischaemic events -- HF incidence and prevalence are expected to increase further.[2](#ejhf1452-bib-0002){ref-type="ref"}, [3](#ejhf1452-bib-0003){ref-type="ref"}, [4](#ejhf1452-bib-0004){ref-type="ref"} Despite advances in HF treatment, HF remains a disabling disorder that severely affects patients\' prognosis and quality of life, and is associated with a high economic burden.[5](#ejhf1452-bib-0005){ref-type="ref"} Therefore, it is important to identify additional therapeutic strategies to improve the outcome of HF patients.

Cardiac glycosides have been used for the treatment of chronic HF for centuries. However, prospective trials investigating the impact of randomized initiation or withdrawal of cardiac glycoside therapy on all‐cause mortality or morbidity[6](#ejhf1452-bib-0006){ref-type="ref"}, [7](#ejhf1452-bib-0007){ref-type="ref"}, [8](#ejhf1452-bib-0008){ref-type="ref"}, [9](#ejhf1452-bib-0009){ref-type="ref"} in patients with HF and a reduced ejection fraction (HFrEF), respectively, failed to provide sufficient evidence and were exclusively performed using digoxin. The only randomized controlled and adequately powered trial investigating the impact of cardiac glycosides on mortality risk in HFrEF is the DIG trial. There, treatment with digoxin had no impact on mortality in the overall trial population,[6](#ejhf1452-bib-0006){ref-type="ref"} but significantly reduced hospitalizations for worsening HF by 28%. Baseline treatment of patients in the DIG trial included diuretics (81%) and angiotensin‐converting enzyme inhibitors (ACEi, 94%) according to guidelines at that time, but not beta‐blocker. A post‐hoc analysis indicated that HF patients \[New York Heart Association (NYHA) class II--IV\] treated with digoxin at serum concentrations of 0.5--0.9 ng/L (i.e. lower spectrum of the formerly used therapeutic range of 0.5--2.0 ng/mL) experienced a statistically significant mortality risk reduction (−19% to −23%) compared to placebo. In contrast, patients treated with digoxin at serum concentrations \> 1.2 ng/mL had a significant increase in overall mortality.[10](#ejhf1452-bib-0010){ref-type="ref"}, [11](#ejhf1452-bib-0011){ref-type="ref"}, [12](#ejhf1452-bib-0012){ref-type="ref"}

Current European Society of Cardiology (ESC) HF guidelines suggest treatment with cardiac glycosides as an option in patients with persistent symptoms despite optimal pharmacological therapy including ACEi/angiotensin receptor blocker (ARB), beta‐blocker, mineralocorticoid receptor antagonist (MRA), angiotension receptor--neprilysin inhibitor (ARNI), as well as cardiac resynchronization therapy (CRT) and ivabradine, if indicated.[1](#ejhf1452-bib-0001){ref-type="ref"} Furthermore, treatment with cardiac glycosides is recommended for rate control in HF patients with atrial fibrillation according to both ESC HF and atrial fibrillation guidelines.[1](#ejhf1452-bib-0001){ref-type="ref"}, [13](#ejhf1452-bib-0013){ref-type="ref"} Nevertheless, prescription rates of cardiac glycosides of currently 20--25% in European and ≈10% in U.S. HFrEF patient populations are steadily declining,[14](#ejhf1452-bib-0014){ref-type="ref"}, [15](#ejhf1452-bib-0015){ref-type="ref"}, [16](#ejhf1452-bib-0016){ref-type="ref"} possibly related to concerns about cardiac glycoside toxicity and because prospective randomized evidence in HF patients treated according to current standards is lacking.

Digitoxin shares the pharmacodynamic effects as digoxin, but has a more stable pharmacokinetic profile. Compared to digoxin, stable digitoxin serum levels are better maintained during treatment and the drug does not accumulate in patients with impaired renal function. This applies even in the elderly, in whom digitoxin dosage often has to be reduced because of a reduced skeletal muscle mass taking into account the high protein binding and main distribution of digitoxin in this compartment. Clinical drug--drug interactions extensively researched for in cardiac glycosides also have to be accounted for digitoxin.[17](#ejhf1452-bib-0017){ref-type="ref"} However, despite its similar pharmacodynamic but favourable pharmakokinetic profile compared to digoxin, adequately powered trials reporting on the effect of treatment with digitoxin on hard clinical endpoints in patients with HF are lacking.

Based on these considerations, DIGIT‐HF (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure) aims to determine the therapeutic potential and safety of digitoxin in a randomized, blinded and controlled clinical trial design with adequate sample size in patients with HFrEF on top of optimized HF treatment.

Study design {#ejhf1452-sec-0005}
============

The DIGIT‐HF trial is a pragmatic, multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled, phase IV trial. The objective is to demonstrate that digitoxin preferably ranging at serum concentrations of 8--18 ng/mL (10.5--23.6 nmol/L) on top of standard of care (SOC) reduces the composite endpoint of all‐cause mortality or first hospital admission for worsening HF (whatever occurs first) in patients with advanced chronic HFrEF.

Trial population {#ejhf1452-sec-0006}
----------------

Adult patients may enter the screening phase if they present with advanced chronic HFrEF of NYHA functional class III--IV and left ventricular ejection fraction ≤ 40%, or NYHA functional class II and left ventricular ejection fraction ≤ 30%. After the screening visit, patients suitable for study enrolment by meeting all inclusion (*Table* [1](#ejhf1452-tbl-0001){ref-type="table"}) and not violating any exclusion criteria (*Table* [2](#ejhf1452-tbl-0002){ref-type="table"}) are randomized in a 1:1 fashion to either digitoxin or placebo treatment. A total number of 2190 patients in approximately 50 study centres in Germany and Austria will be included (1095 per group). All patients receive SOC as recommended by ESC guidelines,[1](#ejhf1452-bib-0001){ref-type="ref"} building on treatment with beta‐blocker, ACEi/ARB, MRA, as well as, if indicated, ARNI, ivabradine, CRT, and implantable cardioverter‐defibrillators upon the discretion of the treating physician. If present at baseline, cardiac glycoside pre‐treatment is stopped and immediately switched to double‐blind study medication. Inclusion of patients previously treated with cardiac glycosides was considered important because this is a relevant subpopulation with more advanced HF[18](#ejhf1452-bib-0018){ref-type="ref"}, [19](#ejhf1452-bib-0019){ref-type="ref"} and exclusion of these patients may lead to selection of a healthier patient population with lower event rates. However, because of potential withdrawal effects in patients with cardiac glycoside pre‐treatment, we re‐analysed data from the DIG trial. In the DIG trial, about 44% of patients received digoxin before randomization and were treated in a randomized withdrawal design, whereas 56% of patients were not treated with digoxin before randomization and were treated *de novo* with digoxin or placebo. In the subgroup analysis reported in the DIG trial, results on the composite of death or hospitalization for worsening HF of patients who received and did not receive digoxin before randomization were consistent with the overall trial population.[6](#ejhf1452-bib-0006){ref-type="ref"} In addition, the original data from the DIG trial requested and received from the National Heart, Lung, and Blood Institute (NHLBI) were analysed to exclude differential effects of withdrawal and onset of digoxin on endpoints and no inconsistencies were found. Based on these results, withdrawal effects by inclusion of patients previously treated with cardiac glycosides are not expected. Nonetheless, randomization is stratified for previous cardiac glycoside use and a subgroup analysis is planned to detect potential withdrawal effects.

###### 

Inclusion criteria

  ----- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\.   Signed written informed consent and willingness to comply with treatment and follow‐up
  2\.   Male and female patients aged ≥ 18 years at the day of inclusion
  3\.   Capable to understand the investigational nature, potential risks and benefits of the clinical trial
  4\.   Chronic heart failure with symptoms compatible with New York Heart Association functional class III--IV and a left ventricular ejection
        fraction ≤ 40%, or New York Heart Association functional class II with left ventricular ejection fraction ≤ 30% (determined at screening by
        echocardiography or cardiac magnetic resonance tomography or within 8 weeks prior to study inclusion by left ventricular angiography,
        echocardiography, radionuclide ventriculography, cardiac magnetic resonance tomography)
        AND
        a heart failure therapy based on current ESC guideline recommendations for a duration of at least 6 months upon
        discretion of the treating physician
  5\.   Women without childbearing potential defined as one or more of the following:
        a\. Women at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy with or without hysterectomy at theday of inclusion
        b\. Women ≥ 50 years of age at the day of inclusion who have been postmenopausal since at least 1 year
        c\. Women \< 50 years and in postmenopausal state ≥ 1 year with serum FSH \> 40 IU/L (ascertained by a second laboratory assessment after 4 weeks)
        OR
        Women of childbearing potential who have a negative hCG pregnancy test and agree to meet one or more of the following
        criteria from the time of screening/baseline, during the study and for a period of 40 days following the last administration of study medication:
        a\. Correct use of reliable contraception methods. This includes hormonal contraceptive (oral contraceptives, implants, transdermal patches,hormonal vaginal devices or injections with prolonged release) or an intrauterine device/system or a barrier method of contraception suchas condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam/gel/film/cream/suppository)
        b\. True abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)
        c\. Sexual relationship only with female partners and/or sterile male partnersORMen
  ----- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Exclusion criteria

  ------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\.    Recent (\< 2 months ago): myocardial infarction, coronary revascularization, surgery or catheter intervention for valvular heart disease, acute coronary syndrome, stroke or cerebral ischaemia, start of heart failure device therapy potentially improving left ventricular ejection fraction or heart failure symptoms (e.g. cardiac resynchronization therapy, cardiac contractility modulation, baroreflex activation therapy)
  2\.    Scheduled surgery or catheter intervention for valvular heart disease or scheduled coronary revascularization
  3\.    Active myocarditis
  4\.    Complex congenital heart disease; this does not include: mild‐moderate valve disease, uncomplicated shunts (isolated patent foramen ovale, small atrial or ventricular septum defects without associated lesions), repaired secundum or sinus venosus atrial septal defects or ventricular septal defects without residua, previously ligated or occluded ductus arteriosus
  5\.    High‐urgency listing for heart transplantation or scheduled therapy with left ventricular assist device
  6\.    Heart rate \< 60 b.p.m. (except if functional cardiac resynchronization therapy in place)
  7\.    Sinoatrial/atrioventricular block \>I degree, sick sinus syndrome or carotid sinus syndrome (except if pacemaker protected)
  8\.    Proven or suspected accessory, atrioventricular pathways (e.g. Wolff--Parkinson--White syndrome)
  9\.    History of symptomatic or sustained (≥ 30 s) ventricular arrhythmia unless a cardioverter‐defibrillator implanted
  10\.   Current ventricular tachycardia or fibrillation (this means patients presenting with a running ventricular tachycardia or fibrillation. If ventricular arrhythmias are terminated and a cardioverter‐defibrillator is implanted, inclusion is allowed according to point 9)
  11\.   Hypertrophic obstructive cardiomyopathy (idiopathic subaortic stenosis)
  12\.   Cor pulmonale
  13\.   Constrictive pericarditis
  14\.   Thoracic aortic aneurysm (defined as diameter ≥ 45 mm)
  15\.   Concomitant severe liver and renal disease
  16\.   Persistent hypokalaemia (\< 3.2 mM)
  17\.   Hypercalcaemia or hypomagnesaemia, if clinically suspected and verified by laboratory testing (e.g. hyperparathyroidism, neoplasia‐induced hypercalcaemia, signs of neuromuscular hyperexcitability)
  18\.   Present (within 6 weeks before baseline/day 0 visit) and continuous treatment with amiodarone \[single or short‐term (up to 3 days), not continuous administration of amiodarone immediately before or during study treatment are acceptable\]
  19\.   Scheduled DCC in the next 24 h (e.g. patients not on cardiac glycosides with new‐onset atrial fibrillation. Patients already included and on treatment with IMP can continue IMP and study when scheduled for DCC)
  20\.   Presence of both treatment with cardiac glycosides and atrial fibrillation
  21\.   Simultaneous intravenous treatment with calcium salts
  22\.   Evidence of cardiac glycoside intolerance or known hypersensitivity to any component of IMP
  23\.   Suspected intoxication with cardiac glycosides
  24\.   Unlikely compliance with protocol requirements
  25\.   Pregnant and lactating women
  26\.   Use of other investigational drugs or devices at the time of enrolment, or within 30 days prior to enrolment or 5 half‐lives for investigational drugs, whichever is longer
  27\.   Life expectancy \< 12 months (e.g. due to active cancer)
  ------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DCC, direct current cardioversion; IMP, investigational medicinal product.

Patients with atrial fibrillation represent a substantial subgroup of patients with HFrEF. DIGIT‐HF aims to represent a common HFrEF population with a substantial proportion of atrial fibrillation, which is confirmed by current baseline characteristics with about 25% of patients having atrial fibrillation recruited to DIGIT‐HF. There is no proportion of patients with atrial fibrillation specified within the overall population of the trial. In order to balance prognostic differences, randomization is stratified for atrial fibrillation and respective subgroup analyses for all stratification factors will be carried out. Patients with atrial fibrillation are not excluded unless they are already treated with cardiac glycosides because randomization to placebo with termination of pre‐existing cardiac glycoside therapy could cause significant tachyarrhythmia. As atrial fibrillation is frequent in patients with HF and cardiac glycosides are commonly used for heart rate control, in the study protocol clear procedures were defined for treatment of atrial fibrillation during the course of the trial based on ESC guidelines for the treatment of HF and atrial fibrillation[1](#ejhf1452-bib-0001){ref-type="ref"}, [13](#ejhf1452-bib-0013){ref-type="ref"} (e.g. rhythm/rate control, direct current cardioversion, amiodarone use) (online supplementary material, *DIGIT‐HF study protocol*, *Chapter 5.4, Treatment of atrial fibrillation*). In particular, termination of study medication is defined if sufficient rate control requires treatment with cardiac glycosides or amiodarone, which are also exclusion criteria at baseline (exclusion criteria no. 18 and 20). Minimal or maximal heart rates are not specified at presence of atrial fibrillation at baseline. However, a heart rate ≤ 60 b.p.m. excludes patients with sinus rhythm as well as atrial fibrillation except if functional CRT is in place (exclusion criteria no. 6).

Study flow and dose adjustment {#ejhf1452-sec-0007}
------------------------------

Digitoxin or matching placebo is given orally as continuous treatment until the end of the study on top of SOC. The target range of digitoxin serum concentration is 8--18 ng/mL (10.5--23.6 nmol/L) throughout the study. The starting dose is 0.07 mg digitoxin once daily (o.d.) or placebo. After 6 weeks of treatment, serum concentrations of digitoxin are determined in a core laboratory and dose adjustments are initiated centrally to avoid unblinding. In the placebo group, dose adjustment is randomly assigned. In the digitoxin group, dose adjustment employs a pre‐defined algorithm. If digitoxin serum levels are outside the target range, doses are reduced or increased to 0.05 or 0.1 mg digitoxin o.d., accordingly. Otherwise, the dose of digitoxin is maintained. In patients requiring up‐titration, a second measurement of digitoxin serum concentrations is performed 6 weeks later (i.e. 12 weeks after randomization) to confirm digitoxin serum concentrations within the target range. Again, in the placebo group, dose adjustment is randomly assigned. In the digitoxin group, dose is reduced to 0.07 mg o.d. if serum concentration is above target range. Otherwise, the present dose of 0.1 mg digitoxin o.d. is maintained. An overview of the study flow is depicted in *Figure* [1](#ejhf1452-fig-0001){ref-type="fig"}.

![Flowchart of the DIGIT‐HF trial.](EJHF-21-676-g001){#ejhf1452-fig-0001}

If digitoxin serum levels after 6 weeks exceed a concentration of 25 ng/mL (33 nmol/L), i.e. the upper limit of the therapeutic range formerly used in clinical practice, it is considered highly unlikely that the target range can be achieved with the above described dose adjustment. For safety reasons (as the study hypothesis is based on association between mortality and serum concentrations retrospectively observed in the DIG trial), patients with digitoxin serum levels \> 25 ng/mL (\> 33 nmol/L) should not continue digitoxin treatment with the proposed doses. In these patients, an adapted dose adjustment will be performed. If digitoxin serum concentrations are \> 25 ng/mL (\> 33 nmol/L) after 6 weeks, treatment will be paused for 6 weeks and re‐started with a dose of 0.05 mg taken every second day. If digitoxin serum levels determined 12 weeks or 12 months after randomization (the latter time‐point applicable only for scientific and safety reasons, see below) exceed 25 ng/mL (33 nmol/L), patients should not continue active treatment for safety reasons. To keep the trial pragmatic and to avoid unblinding of these patients, treatment is then switched to placebo. Digitoxin serum concentrations are also determined in all patients after 12 months for scientific and safety reasons only.

Outpatient follow‐up is scheduled every 6 months. The course of the disease including severity, signs and symptoms of HF, and medication are documented in detail. Quality of life is assessed at baseline and after 12 months by means of the 12‐item Short‐Form Health Survey. All patients will be followed until the end of the study and will have an end of treatment visit.

Outcomes {#ejhf1452-sec-0008}
--------

The primary endpoint is a composite of all‐cause mortality and hospital admission for worsening HF (whatever occurs first). The latter is defined by the presence of all of the following: (i) worsening of HF based on clinical judgement (presence of HF symptoms) by the treating physician; (ii) hospital stay overnight; and (iii) intravenous treatment with diuretics or vasoactive substances (e.g. nitroglycerine) or inotropes (e.g. dobutamine).

Key secondary endpoints are components of the composite and recurrent hospital admission for worsening HF. Further secondary endpoints are cardiovascular death, death from HF, any non‐cardiovascular death, fatal or non‐fatal myocardial infarction, fatal or non‐fatal stroke, any cardiovascular hospitalization, hospital admission for any cause, implantation of a cardioverter‐defibrillator, implantation of a CRT device, implantation of a pacemaker, sudden cardiac death, and change in NYHA functional class.

Safety and tolerability of treatment are documented and adverse events, serious adverse events and laboratory abnormalities will be compared between the two treatment groups.

Blinding and randomization {#ejhf1452-sec-0009}
==========================

The study is double‐blind. Randomization is stratified by centre, sex, NYHA functional class (II, III, or IV), atrial fibrillation, and pre‐treatment with cardiac glycosides at baseline. Randomization, assessment of digitoxin serum levels and blinded dose adjustment are performed centrally via a web portal, which is also used for emergency unblinding if necessary. Placebo patients receive random dose adjustments. Investigators can stop or pause study medication without unblinding the patient, if deemed necessary.

Study duration {#ejhf1452-sec-0010}
--------------

Patients are followed until 734 adjudicated primary events have been recorded. At 367 (50%) events an interim analysis is planned, and the study may be terminated for proven efficacy, but not for futility. This interim analysis is performed by an independent statistician and termination for proven efficacy is judged by the independent Data Monitoring Committee (see below) to maintain blinding. All patients will be followed until the end of the study. A final visit will be conducted for each patient 40 days after finishing treatment with the study medication; patients who withdraw study participation are encouraged to take part in this final visit and in follow‐up via telephone visits. At the end of the study, patient treatment including cardiac glycosides is left at the discretion of the treating physician, who may request unblinding of the patient at this time‐point.

Statistical analysis {#ejhf1452-sec-0011}
--------------------

The primary analysis is based on the intention‐to‐treat population, which comprises all randomized patients who took at least one dose of the study drug. The primary null hypothesis of this study is that both treatment groups have equal hazard rates. This null hypothesis will be evaluated with a multivariable Cox proportional hazards regression model including the time to death or first hospitalization for worsening HF as a dependent variable, and study treatment allocation (digitoxin or placebo), centre, sex, NYHA functional class (II, III, or IV), atrial fibrillation, and treatment with cardiac glycosides at baseline as independent factors. Superiority of digitoxin over placebo regarding the composite endpoint can be concluded if the median time to event is longer in the digitoxin‐treated group and the corresponding *P*‐value of the treatment effect estimated from the Cox regression model is less than the pre‐specified two‐sided significance level of 1% at interim or 4.5% in the final analysis.[20](#ejhf1452-bib-0020){ref-type="ref"}

As soon as the primary hypothesis is rejected, non‐inferiority of digitoxin against placebo concerning all‐cause mortality will be assessed as the first secondary analysis to exclude detrimental effects. Non‐inferiority will be concluded if the upper bound of the one‐sided 97.5% confidence interval of the digitoxin/placebo hazard ratio is below 1.303, whereby the hazard ratio and the confidence interval are derived from a Cox regression model as specified for the primary analysis. Superiority will be concluded if there is a significant difference between digitoxin and placebo regarding overall survival in the respective Cox regression model as specified for the primary analysis (i.e. the upper bound of the one‐sided 97.5% confidence interval of the digitoxin/placebo hazard ratio is below 1). If superiority of digitoxin over placebo regarding overall mortality is demonstrated, substudies will be tested at the significance level of 5%. Otherwise, substudy analysis will be conducted non‐confirmatory. There are no multiplicity issues as the test procedure is hierarchical. All secondary analyses will be explorative. Adverse events, serious adverse events and laboratory abnormalities will be compared between treatment groups with a chi‐square test and other appropriate tests.

Determination of sample size {#ejhf1452-sec-0012}
----------------------------

The required sample size is estimated for a log‐rank test. Assumptions are based on the data from the SHIFT trial (ISRCTN70429960).[21](#ejhf1452-bib-0021){ref-type="ref"} Since eligible patients are expected to have a more severe heart disease than patients studied in SHIFT, it is assumed that the treatment effect of digitoxin is in the same order as the effect of ivabradine observed in the SHIFT trial, although some of the patients are treated with ivabradine as part of SOC. Based on the SHIFT trial, event rates of 26% (digitoxin) and 31% (placebo) after 24 months are expected for the primary outcome (2% were added to the rates of 24% vs. 29% for the composite of hospitalization for HF or cardiovascular death reported in SHIFT, because all‐cause mortality was 2% higher than cardiovascular mortality). Exponential survival is assumed. Additionally, it is assumed that adjustment for stratification variables -- as planned for the primary analysis -- will not reduce power. The two‐sided family‐wise type‐I error rate is set to 0.05 (0.01 at interim and 0.045 at the final analysis[20](#ejhf1452-bib-0020){ref-type="ref"}) and the power is set to 0.8. The required sample size is estimated for an accrual period of 36 months and a maximum length of follow‐up of 48 months. Under these assumptions, a total of 2190 patients (1095 patients per group) with 734 events (total) is required to prove superiority of digitoxin over placebo. Should recruitment of patients require more time than anticipated, the follow‐up period will be extended and because this is an event‐driven trial, a smaller sample size will then be needed to observe the required number of events.

Substudies {#ejhf1452-sec-0013}
----------

Pre‐specified substudies will investigate the effect of digitoxin on endothelial function, arrhythmic burden, left ventricular remodelling and function, and exercise capacity. Substudies will be included in the hierarchical test procedure of the trial after primary and key secondary analyses have been performed. The hierarchical order of testing will be determined before unblinding.

Trial organization {#ejhf1452-sec-0014}
------------------

The principal investigators and the Hannover Clinical Trail Center (HCTC) representing the trial sponsor (Hannover Medical School) are responsible for all aspects of the study protocol and amendments. The trial Steering Committee ensures scientific quality in all study‐related aspects. An independent Data Monitoring Committee is responsible for reviewing unblinded safety data at regular intervals during the study and may recommend stopping the trial because of harmful effects. An independent Clinical Event Adjudication Committee (CEAC) will rate all causes and circumstances of hospitalizations and death according to pre‐specified criteria in the CEAC charter.

This study is conducted in compliance with the German Drug Law (AMG), the German Good Clinical Practice (GCP) ordinance, ICH GCP guidelines, and other applicable ethical and regulatory requirements. The study is supported by the Federal Ministry of Education and Research (BMBF) under grant number 01KG1303. The DIGIT‐HF trial is registered at EudraCT (2013--005326‐38). Further information can be obtained from the trial protocol (online supplementary material, *DIGIT‐HF study protocol*).

Discussion {#ejhf1452-sec-0015}
==========

Study rationale {#ejhf1452-sec-0016}
---------------

The effect of cardiac glycosides on patient outcome remains unclear despite the long history of its clinical use and available data from prospective randomized trials[6](#ejhf1452-bib-0006){ref-type="ref"}, [7](#ejhf1452-bib-0007){ref-type="ref"}, [8](#ejhf1452-bib-0008){ref-type="ref"} in HF (see comparison of RADIANCE, PROVED, and DIG with DIGIT‐HF in the online supplementary *Table S1*). While the prescription rates of cardiac glycosides declined substantially in recent years, it is unclear whether this is justified against the benefit in HF hospitalizations seen with digoxin in the DIG trial (number needed to treat for 3 years to avoid one HF hospitalization: 10--12).[6](#ejhf1452-bib-0006){ref-type="ref"}, [10](#ejhf1452-bib-0010){ref-type="ref"}, [11](#ejhf1452-bib-0011){ref-type="ref"}, [12](#ejhf1452-bib-0012){ref-type="ref"} Moreover, the large randomized trials showing the benefits of ACEi, beta‐blockers, MRA, ivabradine, CRT, and recently also ARNI, have been performed with sizable proportions of background therapy including cardiac glycosides, i.e. in 25--90% of the study populations.[21](#ejhf1452-bib-0021){ref-type="ref"}, [22](#ejhf1452-bib-0022){ref-type="ref"}, [23](#ejhf1452-bib-0023){ref-type="ref"}, [24](#ejhf1452-bib-0024){ref-type="ref"}, [25](#ejhf1452-bib-0025){ref-type="ref"}, [26](#ejhf1452-bib-0026){ref-type="ref"}, [27](#ejhf1452-bib-0027){ref-type="ref"}, [28](#ejhf1452-bib-0028){ref-type="ref"} Currently, it is unclear whether the above listed interventions may have exerted their benefits independent of cardiac glycoside treatment. Importantly, the survival benefit of spironolactone on top of a background therapy with ACEi (95% of trial population) in the RALES trial was only significant in patients receiving digoxin; in this trial, background therapy with beta‐blocker was very low (10%), but was high with cardiac glycosides (75%).[27](#ejhf1452-bib-0027){ref-type="ref"} In addition, a recent retrospective analysis of the DIG trial using entry criteria (heart rate \> 70 b.p.m.) and the primary composite endpoint used in SHIFT (i.e. cardiovascular death or hospital admission for worsening HF) found a similar risk reduction regarding both the composite outcome and its components among patients receiving digoxin or ivabradine.[29](#ejhf1452-bib-0029){ref-type="ref"} Yet, data demonstrating the impact of cardiac glycosides on mortality and morbidity in patients with HF and atrial fibrillation are scarce and only available from observational studies or retrospective analyses. Results were conflicting and contradictory, even if performed in the same data set. This was mainly due to limitations such as prescription bias and invisible confounders, which cannot be biometrically rectified, as well as missing information on cardiac glycoside serum concentrations for proper risk adjustment.[18](#ejhf1452-bib-0018){ref-type="ref"}, [19](#ejhf1452-bib-0019){ref-type="ref"}, [30](#ejhf1452-bib-0030){ref-type="ref"}

Drug and dose rationale {#ejhf1452-sec-0017}
-----------------------

In contrast to digoxin, no trial has yet investigated the effect of digitoxin on clinically relevant cardiovascular endpoints in HF patients, despite its more stable pharmacokinetics and higher pharmacological stability.[17](#ejhf1452-bib-0017){ref-type="ref"} In patients with chronic HF (NYHA class II--III), daily administration of 0.07 mg digitoxin decreased end‐systolic diameters and increased posterior wall motion amplitude, stroke volume, shortening fraction, and early diastolic left ventricular filling speed.[31](#ejhf1452-bib-0031){ref-type="ref"} When applied at mean doses of 0.06--0.07 mg o.d., digitoxin serum concentrations remained constantly low, ranging between 6.4--9.4 ng/mL (8.5--12.2 nM) -- even in patients with impaired renal function.[32](#ejhf1452-bib-0032){ref-type="ref"} Concentrations of digitoxin in a range of 8--18 ng/mL increased parameters of systolic function in dose--response analyses in man equivalent to digoxin concentrations of 0.5--0.9 ng/mL,[33](#ejhf1452-bib-0033){ref-type="ref"} i.e. the concentration associated with a reduced overall mortality risk in patients with HFrEF studied in the DIG trial.[6](#ejhf1452-bib-0006){ref-type="ref"} Our own studies demonstrated that treatment of endothelial cells with digitoxin at concentrations of 10--30 nM (7.65--22.95 ng/mL) effectively inhibited cytokine‐induced pro‐inflammatory processes (e.g. expression of monocyte chemoattractant protein‐1, vascular cell adhesion molecule‐1, monocyte adhesion), production of reactive oxygen species and apoptosis, but increased the expression and activation of the endothelial nitric oxide synthase.[34](#ejhf1452-bib-0034){ref-type="ref"} Based on these studies, concentrations of digitoxin ≥ 8 ng/mL seem to be necessary for improving myocardial function, endothelial dysfunction[35](#ejhf1452-bib-0035){ref-type="ref"} and ultimately prognosis in patients with advanced chronic HFrEF. Therefore, digitoxin target serum concentrations of 8--18 ng/mL (10.5--23.6 nmol/L) were chosen for the DIGIT‐HF trial. Analysis of blinded dose adjustments to achieve target serum concentrations in the first 300 patients randomized into DIGIT‐HF verified the chosen dose adjustment protocol supporting simplicity of trial conduct.[36](#ejhf1452-bib-0036){ref-type="ref"} The verified dose adjustment protocol also supports safe use of digitoxin even in elderly patients with a reduced skeletal muscle mass and hence reduced volume of distribution due to the high protein binding of digitoxin. Possible pharmacodynamic and pharmacokinetic drug--drug interactions between digitoxin and a variety of drugs have to be taken into account. However, recommendations not to use certain concomitant medication affecting pharmacodynamics and pharmacokinetics (e.g. colestyramine, colestipol) in the study protocol (online supplementary material, *DIGIT‐HF study protocol*, *Chapter 5.4, Concomitant therapy*) and in particular the exclusion of amiodarone, which is known to reduce hepatic digitoxin metabolism by inducing enzyme inhibition resulting in significantly increased digitoxin levels,[17](#ejhf1452-bib-0017){ref-type="ref"} seem to be effective measures to avoid serious side effects so far.

Although direct comparison of digoxin with digitoxin on outcome in HFrEF in a prospective, placebo‐controlled, randomized clinical trial would be preferable, implementation of this trial most likely will not be feasible. However, if present data of the DIG trial are supported by the outcome data of DIGIT‐HF and because of the almost identical pharmacodynamic properties,[17](#ejhf1452-bib-0017){ref-type="ref"} analogous use of digoxin and digitoxin should be possible for evidence‐based HF therapy.

Summary {#ejhf1452-sec-0018}
=======

The DIGIT‐HF clinical outcome trial will provide important and urgently required evidence, whether digitoxin against a background of contemporary drug and device HF therapy may improve mortality and/or morbidity in patients with advanced chronic HFrEF presenting with sinus rhythm or atrial fibrillation.

Funding {#ejhf1452-sec-0019}
-------
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